Pre-eclampsia

Lancet

Volumn 365, Issue 9461, 2005, Pages 785-799

  Sibai, Baha ^a   Dekker, Gus ^b   Kupferminc, Michael ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ASCORBIC ACID; BETAMETHASONE; CORTICOSTEROID; DEXAMETHASONE; DIURETIC AGENT; FISH OIL; HEPARIN; HYDRALAZINE; LABETALOL; LOW MOLECULAR WEIGHT HEPARIN; MAGNESIUM; MAGNESIUM SULFATE; NIFEDIPINE; PHENYTOIN; PLASMA SUBSTITUTE; ZINC;

APOPTOSIS; CALCIUM INTAKE; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CLINICAL TRIAL; COLLOID; CONFERENCE PAPER; CONVULSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; EPIDEMIOLOGICAL DATA; EPIGENETICS; GENE CONTROL; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOME IMPRINTING; HELLP SYNDROME; HIGH RISK PREGNANCY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INTRACYTOPLASMIC SPERM INJECTION; INTRAUTERINE GROWTH RETARDATION; LABOR COMPLICATION; LOW DRUG DOSE; MATERNAL HYPERTENSION; MATERNAL MORBIDITY; MATERNAL MORTALITY; META ANALYSIS; METABOLIC DISORDER; MOTHER FETUS RELATIONSHIP; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERINATAL DEATH; PHENOTYPE; PREDICTION; PREECLAMPSIA; PREMATURE LABOR; PRENATAL CARE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN RESTRICTION; PROTEINURIA; PUERPERIUM; REPRODUCTION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SODIUM RESTRICTION; SYNCYTIOTROPHOBLAST; TREATMENT OUTCOME; TREATMENT PLANNING; VITAMIN SUPPLEMENTATION;

EID: 14644412849     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)71003-5     Document Type: Conference Paper

References (143)

1. Report of the National High Blood Pressure Education Program. Working group report on high blood pressure in pregnancy. Am J Obstet Gynecol. 183:2000;S1-S22
2. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol. 102:2003;181-192
3. Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol. 175:1996;1365-1370
4. Vatten LJ, Skjaerven R. Is pre-eclampsia more than one disease? BJOG. 111:2004;298-302
5. Sibai BM. Prevention of preeclampsia: a big disappointment. Am J Obstet Gynecol. 179:1998;1275-1278
6. Dekker G, Sibai B. Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet. 357:2001;209-215
7. Hauth JC, Ewell MG, Levine RL, Esterlitz JR, Sibai BM, Curet LB. Pregnancy outcomes in healthy nulliparous women who subsequently developed hypertension. Obstet Gynecol. 95:2000;24-28
8. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol. 104:2004;1367-1391
9. Harlow FH, Brown MA. The diversity of diagnosis of preeclampsia. Hypertens Pregnancy. 20:2001;57-67
10. Brown MA, Hague WM, Higgins J, et al. The detection, investigation and management of hypertension in pregnancy: executive summary. Aust N Z J Obstet Gynaecol. 40:2000;133-138
11. Brown MA, Lindheimer MD, de Swiet M, van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: a statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 20:2001;IX-XIV
12. Duley L. Pre-eclampsia and the hypertensive disorders of pregnancy. Br Med Bull. 67:2003;161-176
13. Caritis S, Sibai B, Hauth J, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med. 338:1998;701-705
14. Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol. 100:2002;369-377
15. Hnat MD, Sibai BM, Caritis S, Hiouth J, Lindheimer MD, MacPherson C. Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparous. Am J Obstet Gynecol. 186:2002;422-426
16. Buchbinder A, Sibai BM, Caritis S, et al. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol. 186:2002;66-71
17. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol. 101:2002;6-14
18. Kupferminc MJ. Thrombophilia and pregnancy. Reprod Biol Endocrinol. 1:2003;111-166
19. van Pampus MG, Dekker GA, Wolf H, et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol. 180:1999;1146-1150
20. Sibai BM. Diagnosis, controversies, and management of HELLP syndrome. Obstet Gynecol. 103:2004;981-991
21. Zhang J, Meikle S, Trumble A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy. 22:2003;203-212
22. Ramsay JE, Stewart F, Green IA, Sattar N. Microvascular dysfunction: a link between pre-eclampsia and maternal coronary heart disease. BJOG. 110:2003;1029-1031
23. Wilson BJ, Watson MS, Prescott GJ, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ. 326:2003;1-7
24. Haukkamaa L, Salminen M, Laivuori H, et al. Risk for subsequent coronary artery disease after preeclampsia. Am J Cardiol. 93:2004;805-808
25. Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ. 325:2002;157-160
26. Hack M, Flannery DJ, Schluchter M, et al. Outcomes in young adulthood of very low birth-weight infants. N Engl J Med. 346:2002;149-151
27. Barker DJ. The developmental origins of well-being. Philos Trans R Soc Lond B Biol Sci. 359:2004;1359-1366
28. Helewa ME, Burrows RF, Smith J, et al. Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. CMAJ. 157:1997;715-725
29. Waugh JJS, Clark TJ, Divakaran TG, Khan KS, Kilby MD. Accuracy of urinanalysis dipstick techniques in predicting significant proteinuria in pregnancy. Obstet Gynecol. 103:2004;769-777
30. Durnwald C, Mercer B. A prospective comparison of total protein/creatinine ratio versus 24-hour urine protein in women with suspected preeclampsia. Am J Obstet Gynecol. 189:2003;848-852
31. Al RA, Baykal C, Karacay O, Geyik PO, Altun S, Dolen I. Random urine protein-creatinine ratio to predict proteinuria in new-onset mild hypertension in late pregnancy. Obstet Gynecol. 104:2004;367-371
32. Douglas KA, Redman CWG. Eclampsia in the United Kingdom. BMJ. 309:1994;1395-1400
33. Sibai BM, Hauth J, Caritis S, et al. Hypertensive disorders in twin versus singleton gestations. Am J Obstet Gynecol. 182:2000;938-942
34. Wen SW, Demissie K, Yang Q, Walker MC. Maternal morbidity and obstetric complications in triplet pregnancies and quadruplet and higher-order multiple pregnancies. Am J Obstet Gynecol. 191:2004;254-258
35. Einarsson JI, Sangi-Haghpeykar H, Gardner NO. Sperm exposure and development of preeclampsia. Am J Obstet Gynecol. 188:2003;1241-1243
36. Dekker G, Robillard PY. The birth interval hypothesis - does it really indicate the end of the primipaternity hypothesis? J Reprod Immunol. 59:2003;245-251
37. Saftlas AF, Levine RJ, Klebanoff MA, et al. Abortion, changed paternity, and risk of preeclampsia in nulliparous women. Am J Epidemiol. 157:2003;1108-1114
38. Wang JX, Knottnerus AM, Schuit G, Norman RJ, Chan A, Dekker GA. Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Lancet. 359:2002;673-674
39. Wolfberg AJ, Lee-Parritz A, Peller AJ, Lieberman ES. Association of rheumatic disease with preeclampsia. Obstet Gynecol. 103:2004;1190-1193
40. O'Brien TE, Ray JG, Chan WS. Maternal body mass index and the risk of preeclampsia: a systematic overview. Epidemiology. 14:2003;368-374
41. Cedergren MI. Maternal morbid obesity and the risk of adverse pregnancy outcome. Obstet Gynecol. 103:2004;219-224
42. Wolf M, Sandler L, Munoz K, Hsu K, Ecker JL, Thadhani R. First trimester insulin resistance and subsequent preeclampsia: a prospective study. J Clin Endocrinol Metab. 87:2002;1563-1568
43. Von Dadelszen P, Magee LA. Could an infectious trigger explain the differential maternal response to the shared placental pathology of preeclampsia and normotensive intrauterine growth restriction? Acta Obstet Gynecol Scand. 81:2002;642-648
44. Boggess KA, Lief S, Martha AP, Moos K, Beck J, Offenbacher S. Maternal periodontal disease is associated with an increased risk for preeclampsia. Obstet Gynecol. 101:2003;227-231
45. Nilsson E, Salonen Ros H, Cnattingius S, Lichtenstein P. The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study. BJOG. 111:2004;200-206
46. Laivuori H, Lahermo P, Ollikainen V, et al. Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am J Hum Genet. 72:2003;168-177
47. Oudejans CB, Mulders J, Lachmeijer AM, et al. The parent-of-origin effect of 10q22 in pre-eclamptic females coincides with two regions clustered for genes with down-regulated expression in androgenetic placentas. Mol Hum Reprod. 10:2004;589-598
48. Esplin MS, Fausett MB, Fraser A, et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med. 344:2001;867-872
49. Lie RT, Rasmussen S, Brunborg H, Gjessing HK, Lie-Nielsen E, Irgens LM. Fetal and maternal contributions to risk of pre-eclampsia: a population based study. BMJ. 316:1998;1343-1347
50. Skjaerven R, Wilcox AJ, Lie RT. The interval between pregnancies and the risk of preeclampsia. N Engl J Med. 346:2002;33-38
51. Jivraj S, Anstie B, Cheong YC, Fairlie FM, Laird SM, Li TC. Obstetric and neonatal outcome in women with a history of recurrent miscarriage: a cohort study. Hum Reprod. 16:2001;102-106
52. Redman CWG, Sargent IL. Pre-eclampsia, the placenta, and the maternal systemic inflammatory response - a review. Placenta. 24:2003;S21-S27
53. Wolf M, Kettyle E, Sandler L, Ecker JL, Roberts J, Thadhani R. Obesity and preeclampsia: the potential role of inflammation. Obstet Gynecol. 98:2001;757-760
54. Livingston JC, Barton JR, Park V, Haddad B, Phillips O, Sibai BM. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol. 185:2001;153-157
55. Morrison ER, Miedzybrodzka ZH, Campbell DM, et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost. 87:2002;779-785
56. Chaouat G, Ledee-bataille N, Zourbas S, et al. Implantation: can immunological parameters of implantation failure be of interest for pre-eclampsia? J Reprod Immunol. 59:2003;205-217
57. Robertson SA, Ingman WV, O'Leary S, Sharkey DJ, Tremellen KP. Transforming growth factor beta - a mediator of immune deviation in seminal plasma. J Reprod Immunol. 57:2002;109-128
58. Peters B, Whittall T, Babaahmady K, Gray K, Vaughan R, Lehner T. Effect of heterosexual intercourse on mucosal alloimmunisation and resistance to HIV-1 infection. Lancet. 363:2004;518-524
59. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol. 93:1986;1049-1059
60. Pijnenborg R, Anthony J, Davey DA, et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol. 98:1991;648-655
61. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. J Clin Invest. 99:1997;2152-2164
62. Giudice LC, Conover CA, Bale L, et al. Identification and regulation of the IGFBP-4 protease and its physiological inhibitor in human trophoblasts and endometrial stroma: evidence for paracrine regulation of IGF-II bioavailability in the placental bed during human implantation. J Clin Endocrinol Metab. 87:2002;2359-2366
63. Jaffe R, Dorgan A, Abramowicz JS. Color Doppler imaging of the uteroplacental circulation in the first trimester: value in predicting pregnancy failure or complication. Am J Roentgenol. 164:1995;1255-1258
64. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod. 69:2003;1-7
65. Martin RD. Scaling of the mammalian brain: the maternal energy hypothesis. News Physiol Sci. 11:1996;149-156
66. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol. 2:2002;656-663
67. Croy BA, He H, Esadeg S, Wei Q, et al. Uterine natural killer cells; insight into their cellular and molecular biology from mouse modeling. Reproduction. 126:2003;149-160
68. van der Meer A, Lukassen HG, van Lierop MJ, et al. Membrane-bound HLA-G activates proliferation and interferon-gamma production by uterine natural killer cells. Mol Hum Reprod 2004; 189-95.
69. Hunt JS, Miller L, Vassmer D, Croy BA. Expression of the inducible nitric oxide synthase gene in mouse uterine leukocytes and potential relationships with uterine function during pregnancy. Biol Reprod. 34:1997;419-443
70. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol. 179:1998;1359-1375
71. Hiby SE, Walker JJ, O'Shaughnessy KM, et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med. 200:2004;957-965
72. Huppertz B, Frank HG, Kingdom JC, Reister F, Kaufmann P. Villous cytotrophoblast regulation of the syncytial apoptotic cascade in the human placenta. Histochem Cell Biol. 110:1998;495-508
73. Sargent IL, Germain SJ, Sacks GP, Kumar S, Redman CW. Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol. 59:2003;153-160
74. Hahn S, Holzgreve W. Fetal cells and cell-free fetal DNA in maternal blood: new insights into pre-eclampsia. Hum Reprod Update. 8:2002;501-508
75. Levine RJ, Qian C, Leshane ES, et al. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol. 190:2004;707-713
76. Ishihara N, Matsuo H, Murakoshi H, Laoag-Fernandez JB, Samoto T, Maruo T. Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol. 186:2002;158-166
77. Roberts JM, Lain KY. Recent Insights into the pathogenesis of pre-eclampsia. Placenta. 23:2002;359-372
78. Redline RW, Boyd T, Campbell V, et al. Maternal vascular underperfusion: nosology and reproducibility of placental reaction patterns. Pediatr Dev Pathol. 7:2004;237-249
79. Salomon LJ, Benattar C, Audibert F, et al. Severe preeclampsia is associated with high inhibin A levels and normal leptin levels at 7 to 13 weeks into pregnancy. Am J Obstet Gynecol. 189:2003;1517-1522
80. Saito S, Sakai M. Th1/Th2 balance in preeclampsia. J Reprod Immunol. 59:2003;161-173
81. Mor G, Straszewski S, Kamsteeg M. Role of the Fas/Fas ligand system in female reproductive organs: survival and apoptosis. Biochem Pharmacol. 64:2002;1305-1315
82. Neale D, Demasio K, Illuzi J, Chaiworapongsa T, Romero R, Mor G. Maternal serum of women with pre-eclampsia reduces trophoblast cell viability: evidence for an increased sensitivity to Fas-mediated apoptosis. J Matern Fetal Neonatal Med. 13:2003;39-44
83. Sacks GP, Redman CW, Sargent IL. Monocytes are primed to produce the Th1 type cytokine IL-12 in normal human pregnancy: an intracellular flow cytometric analysis of peripheral blood mononuclear cells. Clin Exp Immunol. 131:2003;490-497
84. Aly AS, Khandelwal M, Zhao J, Mehmet AH, Samuel MD, Parry S. Neutrophils are stimulated by syncytiotrophoblast microvillous membranes to generate superoxide radicals in women with preeclampsia. Am J Obstet Gynecol. 190:2004;252-258
85. Moretti M, Phillips M, Abouzeid A, Cataneo RN, Greenberg J. Increased breath markers of oxidative stress in normal pregnancy and in preeclampsia. Am J Obstet Gynecol. 190:2004;1184-1190
86. Hung TH, Charnock-Jones DS, Skepper JN, Burton GJ. Secretion of tumor necrosis factor-alpha from human placental tissues induced by hypoxia-reoxygenation causes endothelial cell activation in vitro: a potential mediator of the inflammatory response in preeclampsia. Am J Pathol. 164:2004;1049-1061
87. Benyo DF, Smarason A, Redman CW, Sims C, Conrad KP. Expression of inflammatory cytokines in placentas from women with preeclampsia. J Clin Endocrinol Metab. 86:2001;2505-2512
88. Matzinger P. The danger model. Vox Sang. 87:(suppl 2):2004;18
89. Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet. 361:2003;1511-1517
90. Wang Y, Gu Y, Zhang Y, Lewis DF. Evidence of endothelial dysfunction in preeclampsia: decreased endothelial nitric oxide synthase expression is associated with increased cell permeability in endothelial cells from preeclampsia. Am J Obstet Gynecol. 190:2004;817-824
91. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 180:1999;499-506
92. Roberts JM, Redman CWG. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet. 341:1993;1447-1451
93. Redman CW. Platelets and the beginnings of preeclampsia. N Engl J Med. 323:1990;478-480
94. Reister F, Frank HG, Kingdom JC, et al. Macrophage-induced apoptosis limits endovascular trophoblast invasion in the uterine wall of preeclamptic women. Lab Invest. 81:2001;1143-1152
95. Ashton SV, Whitley GS, Dash PR, et al. Uterine spiral artery remodeling involves endothelial apoptosis induced by extravillous trophoblasts through Fas/FasL interactions. Arterioscler Thromb Vasc Biol. 25:2005;102-108
96. Rand J. The annexinpathies: a new category of disease. Biochim Biophys Acta. 1498:2000;169-173
97. Shu F, Sugimura Mkanayama N, Kobayashi H, Kobayashi T, Terao T. Immunohistochemical study of annexin V expression in placentae of preeclampsia. Gynecol Obstet Invest. 49:2000;17-23
98. Schlembach D, Beinder E, Zingsem J, Wunsiedler U, Beckmann MW, Fischer T. Association of maternal and/or fetal factor V Leiden and G20210A prothrombin mutation with HELLP syndrome and intrauterine growth restriction. Clin Sci. 105:2003;279-285
99. Anteby EY, Musalam B, Milwidsky A, et al. Fetal inherited thrombophilias influence the severity of preeclampsia, IUGR and placental abruption. Eur J Obstet Gynecol Reprod Biol. 113:2004;31-35
100. Haig D. Genetic conflicts in human pregnancy. Q Rev Biol. 68:1993;495-532
101. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. Clin Invest. 111:2003;649-658
102. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Am J Obstet Gynecol. 190:2004;1541-1547
103. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 350:2004;672-683
104. Thadhani R, Ecker JL, Mutter WP, et al. Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. Hypertension. 43:2004;988-992
105. Cross JC. The genetics of pre-eclampsia: a feto-placental or maternal problem? Clin Genet. 64:2003;96-103
106. Tjoa ML, Qudejans CBM, Van Vugt JMG, Blankenstein MA, Van Wijk IJ. Markers for presymptomatic prediction of preeclampsia and intrauterine growth restriction. Hypertens Pregnancy. 23:2004;171-189
107. Djurovic S, Clausen T, Wergeland R, Brosstad F, Berg K, Henriksen T. Absence of enhanced systemic inflammatory response at 18 weeks of gestation in women with subsequent pre-eclampsia. BJOG. 109:2002;759-764
108. Chien PF, Arnott N, Gordon A, Owen P, Khan KS. How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An Overview. Br J Obstet Gynaecol. 107:2000;196-208
109. Yu CKH, Papageorghiou AT, Parra M, Dias RP, Nicolaides KH. Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks' gestation. Ultrasound Obstet Gynecol. 22:2003;233-239
110. Yu CKH, Papageorghiou AT, Boli A, Cacho AM, Nicholaides KH. Screening for pre-eclampsia and fetal growth restriction in twin pregnancies at 23 weeks of gestation by transvaginal uterine artery Doppler ultrasound. Obstet Gynecol. 20:2002;535-540
111. Subtil D, Goeusse P, Houfflin-Debarge V, et al. Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo in nulliparous women: the Essai Regional Aspirine Mere-Enfant study (part 2). BJOG. 110:2003;485-491
112. Makrides M, Duley L, Olsen SF. Fish oil, and other prostaglandin precursor supplementation during pregnancy for reducing pre-eclampsia, preterm birth, low birth weight and intrauterine growth restriction. Cochrane Database Syst Rev. 4:2001;CD003402
113. Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan KS. Aspirin for prevention of preeclampsia in women with historical risk factors: a systemic review. Obstet Gynecol. 101:2003;1319-1332
114. Knight M, Duley L, Henderson-Smart DJ, King JF. Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database Syst Rev. 2:2000;CD000492
115. Atallah AN, Hofmeyr GJ, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 1:2002;CD001059
116. North RA, Ferrier C, Gamble G, Fairley KF, Kincaid-Smith P. Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease. Aust N Z J Obstet Gynaecol. 35:1995;357-362
117. Kupferminc MJ, Fait G, Many A, et al. Low molecular weight heparin for the prevention of obstetric complications in women with thrombophilia. Hypertens Pregnancy. 20:2001;35-44
118. Chappell LC, Seed PT, Briley AL, et al. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet. 354:1999;810-816
119. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 1:2001;CD002252
120. Levine RJ, Hauth JC, Curet LB, et al. Trial of calcium to prevent preeclampsia. N Engl J Med. 337:1997;69-76
121. Wallenburg HC, Dekker GA, Makovitz JW, Rotmans P. Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. Lancet. 327:1986;1-3
122. Coomarasamy A, Papaioannou S, Gee H, Khan KS. Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta-analysis. Obstet Gynecol. 98:2001;861-866
123. Coomarasamy A, Braunholtz D, Song F, Taylor R, Khan KS. Individualising use of aspirin to prevent pre-eclampsia: a framework for clinical decision making. BJOG. 110:2003;882-888
124. Friedman SA, Lubarsky S, Schiff E. Expectant management of severe preeclampsia remote from term. Clin Obstet Gynecol. 42:1999;470-478
125. Churchill D, Duley L. Interventionist versus expectant care for severe pre-eclampsia before term. Cochrane Database Syst Rev. 3:2002;CD003106
126. Vigil-DeGracia P, Montufar-Rueda C, Ruiz J. Expectant management of severe preeclampsia and preeclampsia superimposed on chronic hypertension between 24 and 34 weeks' gestation. Eur J Obstet Gynecol Reprod Biol. 107:2003;24-27
127. Haddad B, Deis S, Goffinet F, Paniel BJ, Cabrol D, Siba BM. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation. Am J Obstet Gynecol. 190:2004;1590-1595
128. Weindling AM. The confidential enquiry into maternal and child health (CEMACH). Arch Dis Child. 88:2003;1034-1037
129. Magee LA, Ornstein MP, Von Dadelszen P. Fortnightly review: management of hypertension in pregnancy. BMJ. 318:1999;1332-1336
130. von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 355:2000;87-92
131. Rey E, LeLorier J, Burgess E, Lnage LR, Leduc L. Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ. 157:1997;1245-1254
132. Magee LA, Cham C, Waterman EJ, Ohlsson A, Von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 327:2003;1-10
133. Amorim MMR, Santas LC, Faundes A. Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. Am J Obstet Gynecol. 180:1999;1283-1288
134. Matchaba P, Moodley J. Corticosteroids for HELLP syndrome in pregnancy. Cochrane Database Syst Rev. 4:2002;CD002076
135. Heilmann L, Gerhold S, von Templehoff GF, Pollow K. The role of intravenous volume expansion in moderate pre-eclampsia. Clin Hemorheol Microcirc. 25:2001;83-89
136. Visser W, Wallenburg HCS. Temporising management of severe preeclampsia with and without the HELLP syndrome. Br J Obstet Gynecol. 102:1995;111-117
137. Duley L, Williams J, Henderson-Smart DJ. Plasma volume expansion for treatment of pre-eclampsia. Cochrane Database Syst Rev. 4:1999;CD001805
138. Witlin AG, Sibai BM. Randomized trials for prevention and treatment of eclamptic convulsions. Sibai BM. Hypertensive disorders in women. 2001;221-227 Saunders, Philadelphia
139. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia. Lessons learned from recent trials. Am J Obstet Gynecol. 190:2004;1520-1526
140. Duley L, Galmezoglu AM, Henderson-Smart DJ. Magnesium sulfate and other anticonvulsants for women with preeclampsia. Cochrane Database Syst Rev. 2:2003;CD000025
141. The Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised, placebo-controlled trial. Lancet. 359:2002;1877-1890
142. Mathys LA, Coppage KH, Lambers DS, Barton JR, Sibai BM. Delayed postpartum preeclampsia: an experience of 151 cases. Am J Obstet Gynecol. 190:2004;1464-1466
143. Chames MC, Livingston JC, Ivestor TS, Barton JR, Sibai BM. Late postpartum eclampsia: a preventable disease? Am J Obstet Gynecol. 186:2002;1174-1177